GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevena Inc (NAS:TRVN) » Definitions » Cyclically Adjusted Price-to-FCF

Trevena (Trevena) Cyclically Adjusted Price-to-FCF : (As of May. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Trevena Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Trevena Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Trevena's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trevena Cyclically Adjusted Price-to-FCF Chart

Trevena Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Trevena Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Trevena's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Trevena's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trevena's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trevena's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Trevena's Cyclically Adjusted Price-to-FCF falls into.



Trevena Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Trevena's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Trevena's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.38/129.4194*129.4194
=-0.380

Current CPI (Dec. 2023) = 129.4194.

Trevena Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -9.637 99.695 -12.510
201406 -9.300 100.560 -11.969
201409 -10.598 100.428 -13.657
201412 -11.064 99.070 -14.453
201503 -3.901 99.621 -5.068
201506 -6.320 100.684 -8.124
201509 -6.777 100.392 -8.737
201512 -5.912 99.792 -7.667
201603 -10.137 100.470 -13.058
201606 -8.929 101.688 -11.364
201609 -11.800 101.861 -14.992
201612 -13.029 101.863 -16.554
201703 -12.991 102.862 -16.345
201706 -8.651 103.349 -10.833
201709 -5.435 104.136 -6.755
201712 -4.778 104.011 -5.945
201803 -4.086 105.290 -5.022
201806 -1.916 106.317 -2.332
201809 -1.344 106.507 -1.633
201812 -1.665 105.998 -2.033
201903 -2.161 107.251 -2.608
201906 -0.816 108.070 -0.977
201909 -1.664 108.329 -1.988
201912 -1.833 108.420 -2.188
202003 -1.614 108.902 -1.918
202006 -1.195 108.767 -1.422
202009 -0.472 109.815 -0.556
202012 -1.127 109.897 -1.327
202103 -2.245 111.754 -2.600
202106 -1.843 114.631 -2.081
202109 -1.690 115.734 -1.890
202112 -1.918 117.630 -2.110
202203 -2.757 121.301 -2.942
202206 -1.805 125.017 -1.869
202209 -1.553 125.227 -1.605
202212 -1.298 125.222 -1.342
202303 -1.133 127.348 -1.151
202306 -0.626 128.729 -0.629
202309 -0.639 129.860 -0.637
202312 -0.380 129.419 -0.380

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Trevena  (NAS:TRVN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Trevena Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Trevena's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Trevena (Trevena) Business Description

Industry
Traded in Other Exchanges
Address
955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA, USA, 19087
Trevena Inc is an American biopharmaceutical company focused on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders.
Executives
Mark Corrigan director
Mark Demitrack officer: SVP, Chief Medical Officer 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Robert T Yoder officer: SVP, Chief Business Officer 955 CHESTERBROOK BOULEVARD, SUITE 110, SUITE 200, CHESTERBROOK PA 19087
Carrie L. Bourdow director, officer: President & CEO C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Patricia M. Drake officer: SVP, Chief Commercial Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Barry Shin officer: SVP, CFO C/O TREVENA, INC., 955 CHESTERBROOK BLVD, SUITE 110, CHESTERBROOK PA 19087
Marvin Johnson director C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Moulder Leon O Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Jason Raleigh Nunn director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Anne M. Phillips director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Scott Applebaum officer: CLCO; SVP, Regulatory Affairs C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
John P. Hamill officer: Int. Prin. Fin. Off. and PAO 4092 NEW HOPE ROAD, FURLONG PA 18925